A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Exact Sciences Corp stock. As of the latest transaction made, Fisher Asset Management, LLC holds 122,902 shares of EXAS stock, worth $7.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,902
Previous 159,204 22.8%
Holding current value
$7.06 Million
Previous $6.73 Million 24.41%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$42.43 - $70.83 $1.54 Million - $2.57 Million
-36,302 Reduced 22.8%
122,902 $8.37 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $59,804 - $107,454
1,447 Added 0.92%
159,204 $6.73 Million
Q1 2024

May 09, 2024

BUY
$56.27 - $73.77 $303,745 - $398,210
5,398 Added 3.54%
157,757 $10.9 Million
Q4 2023

Mar 05, 2024

BUY
$59.06 - $75.72 $90,952 - $116,608
1,540 Added 1.02%
152,359 $11.3 Million
Q4 2023

Feb 06, 2024

SELL
$59.06 - $75.72 $209,663 - $268,806
-3,550 Reduced 2.3%
150,819 $11.2 Million
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $2.79 Million - $4.19 Million
42,305 Added 37.75%
154,369 $10.5 Million
Q2 2023

Dec 12, 2023

SELL
$62.68 - $95.05 $2.65 Million - $4.02 Million
-42,305 Reduced 27.41%
112,064 $10.5 Million
Q2 2023

Aug 08, 2023

SELL
$62.68 - $95.05 $1.63 Million - $2.47 Million
-25,954 Reduced 18.8%
112,064 $10.5 Million
Q1 2023

Dec 12, 2023

SELL
$47.19 - $70.77 $1.97 Million - $2.96 Million
-41,794 Reduced 27.07%
112,575 $7.63 Million
Q1 2023

May 01, 2023

SELL
$47.19 - $70.77 $985,091 - $1.48 Million
-20,875 Reduced 13.14%
138,018 $9.36 Million
Q4 2022

Feb 03, 2023

BUY
$30.35 - $53.15 $1.08 Million - $1.89 Million
35,542 Added 28.81%
158,893 $7.87 Million
Q3 2022

Nov 08, 2022

BUY
$31.97 - $49.37 $402,694 - $621,864
12,596 Added 11.37%
123,351 $4.01 Million
Q2 2022

Aug 09, 2022

BUY
$35.61 - $76.23 $2.47 Million - $5.29 Million
69,367 Added 167.6%
110,755 $4.36 Million
Q1 2022

May 05, 2022

BUY
$57.56 - $82.54 $29,240 - $41,930
508 Added 1.24%
41,388 $2.89 Million
Q4 2021

Feb 02, 2022

BUY
$72.5 - $100.68 $1.12 Million - $1.56 Million
15,511 Added 61.14%
40,880 $3.18 Million
Q3 2021

Oct 26, 2021

SELL
$90.24 - $124.05 $247,889 - $340,765
-2,747 Reduced 9.77%
25,369 $2.42 Million
Q2 2021

Jul 27, 2021

BUY
$93.66 - $139.27 $202,586 - $301,241
2,163 Added 8.33%
28,116 $3.5 Million
Q1 2021

Apr 27, 2021

BUY
$116.57 - $155.01 $533,774 - $709,790
4,579 Added 21.42%
25,953 $3.42 Million
Q4 2020

Jan 29, 2021

BUY
$99.61 - $142.12 $495,260 - $706,620
4,972 Added 30.31%
21,374 $2.83 Million
Q3 2020

Nov 10, 2020

BUY
$72.92 - $102.01 $28,220 - $39,477
387 Added 2.42%
16,402 $1.67 Million
Q2 2020

Aug 07, 2020

SELL
$55.75 - $92.75 $17,728 - $29,494
-318 Reduced 1.95%
16,015 $1.39 Million
Q1 2020

Apr 28, 2020

SELL
$37.9 - $104.44 $292,663 - $806,485
-7,722 Reduced 32.1%
16,333 $947,000
Q4 2019

Feb 12, 2020

SELL
$77.66 - $99.74 $3.26 Million - $4.19 Million
-41,985 Reduced 63.58%
24,055 $2.23 Million
Q3 2019

Oct 29, 2019

SELL
$90.37 - $122.49 $190,680 - $258,453
-2,110 Reduced 3.1%
66,040 $5.97 Million
Q2 2019

Jul 30, 2019

BUY
$89.51 - $118.04 $1.5 Million - $1.98 Million
16,771 Added 32.64%
68,150 $8.04 Million
Q1 2019

Apr 22, 2019

SELL
$61.98 - $96.5 $264,778 - $412,248
-4,272 Reduced 7.68%
51,379 $4.45 Million
Q4 2018

Jan 25, 2019

SELL
$56.04 - $82.66 $22,416 - $33,064
-400 Reduced 0.71%
55,651 $3.51 Million
Q3 2018

Oct 24, 2018

BUY
$48.29 - $80.6 $20,764 - $34,658
430 Added 0.77%
56,051 $4.42 Million
Q2 2018

Jul 09, 2018

BUY
$37.84 - $69.96 $1.84 Million - $3.41 Million
48,732 Added 707.39%
55,621 $3.33 Million
Q1 2018

Apr 19, 2018

BUY
$39.82 - $57.53 $21,462 - $31,008
539 Added 8.49%
6,889 $278,000
Q3 2017

Oct 17, 2017

BUY
$37.05 - $47.12 $235,267 - $299,212
6,350
6,350 $299,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.